vs
Acadia Healthcare Company, Inc.（ACHC）与科睿唯安（CLVT）财务数据对比。点击上方公司名可切换其他公司
Acadia Healthcare Company, Inc.的季度营收约是科睿唯安的1.4倍（$829.0M vs $585.5M），Acadia Healthcare Company, Inc.净利率更高（0.5% vs -6.9%，领先7.4%），Acadia Healthcare Company, Inc.同比增速更快（7.5% vs -1.4%），过去两年Acadia Healthcare Company, Inc.的营收复合增速更高（2.0% vs -5.1%）
阿卡迪亚医疗公司是美国的营利性行为医疗健康服务提供商，目前在美国及波多黎各地区运营着超过225家医疗机构，搭建了覆盖广泛的行为健康服务网络，为有相关需求的人群提供专业的心理健康与行为干预服务。
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
ACHC vs CLVT — 直观对比
营收规模更大
ACHC
是对方的1.4倍
$585.5M
营收增速更快
ACHC
高出8.9%
-1.4%
净利率更高
ACHC
高出7.4%
-6.9%
两年增速更快
ACHC
近两年复合增速
-5.1%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $829.0M | $585.5M |
| 净利润 | $4.5M | $-40.2M |
| 毛利率 | — | 67.2% |
| 营业利润率 | — | 5.2% |
| 净利率 | 0.5% | -6.9% |
| 营收同比 | 7.5% | -1.4% |
| 净利润同比 | -50.8% | 61.3% |
| 每股收益（稀释后） | $0.05 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACHCCLVT
| Q1 26 | $829.0M | $585.5M | ||
| Q4 25 | $821.5M | $617.0M | ||
| Q3 25 | $851.6M | $623.1M | ||
| Q2 25 | $869.2M | $621.4M | ||
| Q1 25 | $770.5M | $593.7M | ||
| Q4 24 | $774.2M | $663.0M | ||
| Q3 24 | $815.6M | $622.2M | ||
| Q2 24 | $796.0M | $650.3M |
净利润ACHCCLVT
| Q1 26 | $4.5M | $-40.2M | ||
| Q4 25 | $-1.2B | $3.1M | ||
| Q3 25 | $36.2M | $-28.3M | ||
| Q2 25 | $30.1M | $-72.0M | ||
| Q1 25 | $8.4M | $-103.9M | ||
| Q4 24 | $32.6M | $-191.8M | ||
| Q3 24 | $68.1M | $-65.6M | ||
| Q2 24 | $78.5M | $-304.3M |
毛利率ACHCCLVT
| Q1 26 | — | 67.2% | ||
| Q4 25 | — | 66.8% | ||
| Q3 25 | — | 65.0% | ||
| Q2 25 | — | 67.2% | ||
| Q1 25 | — | 65.1% | ||
| Q4 24 | — | 65.7% | ||
| Q3 24 | — | 66.2% | ||
| Q2 24 | — | 67.2% |
营业利润率ACHCCLVT
| Q1 26 | — | 5.2% | ||
| Q4 25 | -142.4% | 6.7% | ||
| Q3 25 | 4.7% | 7.1% | ||
| Q2 25 | 5.8% | 1.1% | ||
| Q1 25 | 1.7% | -3.5% | ||
| Q4 24 | 4.9% | -9.4% | ||
| Q3 24 | 12.1% | 3.5% | ||
| Q2 24 | 13.4% | -36.9% |
净利率ACHCCLVT
| Q1 26 | 0.5% | -6.9% | ||
| Q4 25 | -143.3% | 0.5% | ||
| Q3 25 | 4.3% | -4.5% | ||
| Q2 25 | 3.5% | -11.6% | ||
| Q1 25 | 1.1% | -17.5% | ||
| Q4 24 | 4.2% | -28.9% | ||
| Q3 24 | 8.4% | -10.5% | ||
| Q2 24 | 9.9% | -46.8% |
每股收益（稀释后）ACHCCLVT
| Q1 26 | $0.05 | $-0.06 | ||
| Q4 25 | $-12.98 | $0.00 | ||
| Q3 25 | $0.40 | $-0.04 | ||
| Q2 25 | $0.33 | $-0.11 | ||
| Q1 25 | $0.09 | $-0.15 | ||
| Q4 24 | $0.36 | $-0.27 | ||
| Q3 24 | $0.74 | $-0.09 | ||
| Q2 24 | $0.85 | $-0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $158.5M | — |
| 总债务越低越好 | $2.5B | $4.3B |
| 股东权益账面价值 | $2.0B | $4.8B |
| 总资产 | $5.5B | $10.9B |
| 负债/权益比越低杠杆越低 | 1.29× | 0.89× |
8季度趋势，按日历期对齐
现金及短期投资ACHCCLVT
| Q1 26 | $158.5M | — | ||
| Q4 25 | $133.2M | $329.2M | ||
| Q3 25 | $118.7M | $318.7M | ||
| Q2 25 | $131.4M | $362.6M | ||
| Q1 25 | $91.2M | $354.0M | ||
| Q4 24 | $76.3M | $295.2M | ||
| Q3 24 | $82.1M | $388.5M | ||
| Q2 24 | $77.2M | $376.4M |
总债务ACHCCLVT
| Q1 26 | $2.5B | $4.3B | ||
| Q4 25 | $2.5B | $4.3B | ||
| Q3 25 | $2.3B | $4.4B | ||
| Q2 25 | $2.3B | $4.5B | ||
| Q1 25 | $2.2B | $4.5B | ||
| Q4 24 | $2.0B | $4.5B | ||
| Q3 24 | $1.9B | $4.6B | ||
| Q2 24 | $1.8B | $4.6B |
股东权益ACHCCLVT
| Q1 26 | $2.0B | $4.8B | ||
| Q4 25 | $1.9B | $4.8B | ||
| Q3 25 | $3.1B | $4.9B | ||
| Q2 25 | $3.1B | $5.0B | ||
| Q1 25 | $3.0B | $5.0B | ||
| Q4 24 | $3.1B | $5.1B | ||
| Q3 24 | $3.0B | $5.5B | ||
| Q2 24 | $3.0B | $5.6B |
总资产ACHCCLVT
| Q1 26 | $5.5B | $10.9B | ||
| Q4 25 | $5.5B | $11.1B | ||
| Q3 25 | $6.4B | $11.2B | ||
| Q2 25 | $6.3B | $11.4B | ||
| Q1 25 | $6.1B | $11.5B | ||
| Q4 24 | $6.0B | $11.5B | ||
| Q3 24 | $5.9B | $12.0B | ||
| Q2 24 | $5.7B | $12.1B |
负债/权益比ACHCCLVT
| Q1 26 | 1.29× | 0.89× | ||
| Q4 25 | 1.28× | 0.89× | ||
| Q3 25 | 0.74× | 0.90× | ||
| Q2 25 | 0.74× | 0.90× | ||
| Q1 25 | 0.72× | 0.90× | ||
| Q4 24 | 0.64× | 0.88× | ||
| Q3 24 | 0.62× | 0.84× | ||
| Q2 24 | 0.62× | 0.83× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $61.5M | $134.7M |
| 自由现金流经营现金流 - 资本支出 | — | $78.9M |
| 自由现金流率自由现金流/营收 | — | 13.5% |
| 资本支出强度资本支出/营收 | — | 9.5% |
| 现金转化率经营现金流/净利润 | 13.78× | — |
| 过去12个月自由现金流最近4个季度 | — | $333.9M |
8季度趋势，按日历期对齐
经营现金流ACHCCLVT
| Q1 26 | $61.5M | $134.7M | ||
| Q4 25 | $-86.3M | $159.9M | ||
| Q3 25 | $73.2M | $181.1M | ||
| Q2 25 | $133.5M | $116.3M | ||
| Q1 25 | $11.5M | $171.2M | ||
| Q4 24 | $116.7M | $141.3M | ||
| Q3 24 | $163.1M | $202.9M | ||
| Q2 24 | $171.1M | $126.2M |
自由现金流ACHCCLVT
| Q1 26 | — | $78.9M | ||
| Q4 25 | $-179.5M | $89.2M | ||
| Q3 25 | $-63.0M | $115.5M | ||
| Q2 25 | $-34.2M | $50.3M | ||
| Q1 25 | $-163.2M | $110.3M | ||
| Q4 24 | $-86.8M | $59.1M | ||
| Q3 24 | $-27.1M | $126.3M | ||
| Q2 24 | $16.9M | $60.3M |
自由现金流率ACHCCLVT
| Q1 26 | — | 13.5% | ||
| Q4 25 | -21.8% | 14.5% | ||
| Q3 25 | -7.4% | 18.5% | ||
| Q2 25 | -3.9% | 8.1% | ||
| Q1 25 | -21.2% | 18.6% | ||
| Q4 24 | -11.2% | 8.9% | ||
| Q3 24 | -3.3% | 20.3% | ||
| Q2 24 | 2.1% | 9.3% |
资本支出强度ACHCCLVT
| Q1 26 | — | 9.5% | ||
| Q4 25 | 11.3% | 11.5% | ||
| Q3 25 | 16.0% | 10.5% | ||
| Q2 25 | 19.3% | 10.6% | ||
| Q1 25 | 22.7% | 10.3% | ||
| Q4 24 | 26.3% | 12.4% | ||
| Q3 24 | 23.3% | 12.3% | ||
| Q2 24 | 19.4% | 10.1% |
现金转化率ACHCCLVT
| Q1 26 | 13.78× | — | ||
| Q4 25 | — | 51.58× | ||
| Q3 25 | 2.02× | — | ||
| Q2 25 | 4.43× | — | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 2.39× | — | ||
| Q2 24 | 2.18× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACHC
| Acute Inpatient Psychiatric Facilities | $471.0M | 57% |
| Other | $140.0M | 17% |
| Specialty Treatment Facilities | $128.0M | 15% |
| Residential Treatment Facilities | $90.0M | 11% |
CLVT
| Subscription | $397.5M | 68% |
| Re-occurring | $108.6M | 19% |
| Transactional | $79.4M | 14% |
